Rebalix
Logo SPDRSPDR · sheet of 10 September 2026
ETF sheet · official issuer and register data

State Street® SPDR® S&P Developed Quality Aristocrats UCITS ETF (Acc)

QDEV · IE000IISJT64 · USD · domicile Ireland
Equity · Global · Dividend · QualitySFDR art. 6 (inferred)
Index tracked: S&P Developed Quality FCF Aristocrats Index
TER
0.35%+ trans. 0.03%
Fund size
34 m EUR
Tracking difference
not computable
🇮🇹 tax rate
26.00%white list 0.00%
Replication
Physical (full replication)
Income
Accumulating
Launch 5 Dec 2024 · costs from the KID as of 2 Sept 2026 · 100 securities held · 8 venues (ESMA register)

The fund’s objective — in the issuer’s words

From the Key Information Document (KID) · 5 Aug 2026
Investment objective The investment objective of the Fund is to track the performance of large and mid-sized equities in 'developed markets" (as such term is defined by the Index Provider) globally ("Developed Markets"). The Fund seeks to track the performance of the S&P Developed Quality FCF Aristocrats Index (the "Index") as closely as possible. The Fund is an index tracking fund (also known as a passively managed fund). Investment policies The Fund invests primarily in securities included in the Index. The Index measures the performance of Developed…

Performance since series start (in euro) — base 100

6 Dec 20248 Sept 2026 · dividends reinvested where declared by the issuer · converted at ECB rates
2025202612083117
High 120 (13 Aug 2026) · low 83 (7 Apr 2025) · last 117. Past performance is not indicative of future results.

Returns in euro

1 year+15.4%
3 yearsseries too young
5 yearsseries too young
10 yearsseries too young
Since series start+16.9%

Risk · 1 / 3 / 5 years

Volatility (ann.)13.03%13.03%
Max drawdown−12.97%−12.97%
Sharpe0.890.89
Sortino1.311.31
Sharpe/Sortino: risk-free = ECB MRO avg; nominal volatility
Rebalix · QDEV · IE000IISJT641
RebalixQDEV · IE000IISJT64 · sheet of 10 September 2026

Tracking difference — year by year

Fund minus index, complete calendar years · declared by the issuer
YearFundIndexTD
2025+20.93%+21.14%−0.21%
2024−3.46%−3.38%−0.08%

Holdings

Portfolio as declared by the issuer · 31 Aug 2026 · 100 securities · top-10 weight = 47.8%
Top holdingsWeight
Microsoft Corporation5.8%
Apple Inc.5.4%
NVIDIA Corporation5.2%
ASML Holding NV5.1%
Roche Holding Ltd4.7%
Broadcom Inc.4.6%
Novartis AG4.6%
Novo Nordisk A/S Class B4.2%
Visa Inc. Class A4.1%
Meta Platforms Inc Class A4.1%
Countries (% of fund)
United States61.4%Switzerland10.1%Netherlands6.3%Australia5.1%Denmark4.5%
Sectors (% of fund)
Information Technology42.7%Health Care19.9%Financials16.2%Consumer Discretionary5.5%Communication Services4.6%

Listing venues

ESMA register (FIRDS) and official exchange lists
QDEV · Börse Düsseldorf, Börse Frankfurt, Börse Hamburg, Börse Hannover, Börse München / gettex, Börse Stuttgart, Tradegate Exchange, Xetra (Deutsche Börse)
+ 11 unmapped venues (MTF, RFQ, professional)

Official documents

Clickable links in the PDF
KID · www.ssga.com/library-content/kids?isin=IE000IISJT64&documentType=kid&c
Factsheet · www.ssga.com/library-content/products/factsheets/etfs/emea/factsheet-e
Prospectus · www.ssga.com/library-content/products/fund-docs/etfs/emea/1-IE-EN-FP-I
The live sheet, always up to date
rebalix.com/en/etf/IE000IISJT64
Series, distributions, holdings and documents refresh daily.
Sheet produced on 10 September 2026 · data as of the dates shown section by section. Sources: official issuer documents (KID, factsheet, NAV series, declared portfolio), ESMA register (FIRDS), European Central Bank (FX), Italian tax authority / issuer (white-list share). Public methodology: rebalix.com/en/methodology. “—” = not published by the source, never estimated.

Informational document generated by rebalix.com: facts only, no recommendations. Not investment advice or investment research under Directive 2014/65/EU (MiFID II), nor an offer or solicitation. Past performance is not indicative of, nor a guarantee of, future results; the value of an investment can go down as well as up. Before any decision read the issuer’s KID and Prospectus; tax treatment depends on individual circumstances. Trademarks and logos belong to their respective owners and only identify the instrument and its issuer: no affiliation, sponsorship or endorsement.

Rebalix · QDEV · IE000IISJT642